Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol
The concussion controversy surrounding Tua Tagovailoa has prompted both the NFL and the NFLPA to revisit the league’s concussion protocol in a move designed to enhance player safetyIn the wake of this controversy, Odyssey is emphasizing the potential value of its PRV-002 novel compound for the treatment of concussions and the benefit of the playersAccording to a report published by Vox, there are approximately 0.41…